]>
IRCT20230618058520N1 IRCT 2023-07-09 Vice Chancellor for Research and Technology, Shahrood Islamic Azad University Investigating the effect of using ketamine on severe and treatment-resistant depression Investigating the effect of injectable ketamine with doses of 0.5 mg/kg on the control of symptoms in patients with treatment-resistant major depressive disorder: a randomized clinical trial 2023-07-05 anticipated 15 Complete https://irct.ir/trial/70826 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment. 2 depression. Intervention group: Intervention group: receiving 0.5mg/kg ketamine as a single intravenous dose - Rotex medica trittau germany. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Mohammad shiroudi
Shahrood, Tehran Boulevard, Shahrood Islamic Azad University
Shahrood Iran (Islamic Republic of) 3613773955 +98 23 3239 1796 dr7sina7sh@gmail.com Islamic Azad University scientific Yousef kolookhi
Shahrood, Tehran Boulevard, Shahrood Islamic Azad University
Shahrood Iran (Islamic Republic of) 3613773955 +98 23 3239 1796 dr.yousefkolookhi.anesthezia@gmail.com Islamic Azad University Iran (Islamic Republic of) Patients with treatment-resistant major depressive disorder based on DSM IV _ TR criteria Being in a depressive episode Failure to respond to antidepressants and shock medications and failure to control symptoms with other methods Intolerance of oral antidepressants no limit no limit Both More serious psychiatric disorders: bipolar 1 and 2 - cyclothymia - psychosis - obsession - ski and affective Addiction or withdrawal from drugs Personality disorder Physical diseases such as: thyroid disorders, diabetes, hypertension, stroke, brain surgeries, etc. Response to drug treatment and control of disease symptoms with drugs Received ECT two months before starting ketamine treatment Receiving antidepressant medication one month before starting ketamine treatment Lack of consent to participate in the study Cardiovascular problems Pregnancy and breastfeeding F33.9 Major depressive disorder, recurrent, unspecified Treatment - Drugs Intervention group: Intervention group: receiving 0.5mg/kg ketamine as a single intravenous dose - Rotex medica trittau germany Depression score in Beck and Hamilton test. Timepoint: Comparison of Hamilton and Beck test results before injection, two days after injection, one week after injection, one month after injection. Method of measurement: The criterion of response to ketamine treatment is a decrease of 50% or more in Beck and Hamilton tests. Vice Chancellor for Research and Technology, Shahrood Islamic Azad University Approved 2022-09-14 Ethics Committee of Shahrood Islamic Azad University University Boulevard - Islamic Azad University shahrood Semnan Iran (Islamic Republic of)